WebDoctor Encyclopedia

Article

Bispecific T-Cell Engager Antibodies

What are bispecific T-cell engager antibodies?

Bispecific T-cell engagers are a type of immunotherapy made from engineered antibodies. A normal antibody grips one target. A bispecific antibody has two different gripping arms: one attaches to a protein on the surface of the cancer cell, and the other attaches to a protein called CD3 on the patient’s own T cells, the immune system’s killer cells.

By holding the T cell and the cancer cell close together, the antibody acts like a bridge or a matchmaker. The T cell is switched on and kills the cancer cell it has been brought next to. This happens even if the T cell would not normally have recognised the cancer.

These medicines are ready-made, “off-the-shelf” products. Unlike CAR-T cell therapy, they do not require a person’s cells to be collected and modified in a laboratory, so treatment can start quickly. They are mainly used for blood cancers that have come back or stopped responding to other treatments, although their use is expanding.

Medicines in this group

Medicine Cancer target Main use
Blinatumomab CD19 B-cell acute lymphoblastic leukaemia
Teclistamab, elranatamab, linvoseltamab BCMA Multiple myeloma
Talquetamab GPRC5D Multiple myeloma
Glofitamab, epcoritamab CD20 Diffuse large B-cell lymphoma and some other lymphomas
Mosunetuzumab CD20 Follicular lymphoma
Tarlatamab DLL3 Small cell lung cancer
Tebentafusp gp100 (with a T-cell receptor arm) Uveal melanoma

A brief history

The idea of using two-armed antibodies to redirect T cells dates back to the 1980s, but early versions were difficult to make and caused severe side effects. Blinatumomab, a small, two-part antibody fragment, was the first to be approved, in the United States in 2014 for acute lymphoblastic leukaemia. Its success led to a wave of new bispecific antibodies, with several approved for myeloma and lymphoma from 2022 onwards.

1. Key facts at a glance

Feature Details
Type of treatment Immunotherapy using engineered antibodies
Main uses Acute lymphoblastic leukaemia, multiple myeloma, B-cell lymphomas; some solid tumours
How it is given Drip into a vein or injection under the skin, depending on the drug
Start of treatment Small “step-up” doses, often with a hospital stay
Duration Fixed courses or continued until the cancer grows, depending on the drug
Main side effects Cytokine release syndrome, nerve-related side effects, infections, low blood counts

2. How it works

Building a bridge

Arm Attaches to Purpose
Cancer arm A protein on the cancer cell, such as CD19, CD20 or BCMA Finds the cancer
T-cell arm CD3 on T cells Switches on the T cell

When both arms are attached, the T cell releases toxic proteins into the cancer cell, causing it to die. The T cell then multiplies and can go on to kill more cancer cells.

Designs of bispecific antibodies

Blinatumomab is very small and is cleared from the body within hours, so it is given as a continuous drip for weeks at a time. Most newer bispecific antibodies are built more like full-size antibodies and last longer in the body, allowing injections weekly or less often.

Why step-up dosing is used

The first doses can trigger a sudden burst of immune activity. To reduce this, treatment starts with one or more small doses, increasing over days to the full dose. Steroids, paracetamol and antihistamines are often given before the first doses.

3. Who it is for

Conditions treated

Condition Role of bispecific T-cell engagers
Acute lymphoblastic leukaemia Blinatumomab for relapsed B-cell ALL, ALL with measurable residual disease, and increasingly as part of first treatment
Multiple myeloma After several previous treatments, including newer combinations
Diffuse large B-cell lymphoma After two or more previous treatments, including after CAR-T
Follicular lymphoma After two or more previous treatments
Small cell lung cancer Tarlatamab after chemotherapy
Uveal melanoma Tebentafusp for some people with spread disease

Who may be suitable

Most people treated with bispecific antibodies have already had several other treatments. Suitability depends on fitness, previous treatments, blood counts and infections. Because the drugs work through T cells, they work best when the immune system still has a reasonable number of healthy T cells.

Bispecific antibodies and CAR-T compared

Feature Bispecific T-cell engagers CAR-T cell therapy
Source Manufactured medicine Your own T cells, modified in a laboratory
Waiting time Can start within days Several weeks for manufacturing
How often given Repeated doses Usually a single infusion
Chemotherapy beforehand Not usually needed Short chemotherapy before infusion
CRS and ICANS Usually milder Can be more severe

Both approaches harness T cells, and some people receive one after the other. The choice depends on the type of cancer, previous treatments, fitness and access.

4. Before treatment

Step Why it is done
Blood tests Blood counts, kidney and liver function
Infection screening Hepatitis B, HIV and others
Scans or bone marrow tests Measure the cancer before starting
Medicines review Steroids and other medicines are planned
Vaccination review Inactivated vaccines may be recommended before treatment
Carer arrangements Someone may need to stay nearby during the first weeks

Staying near the hospital

Because the most serious side effects usually happen after the first few doses, you may need to stay in hospital or close to it for the first days or weeks. Having a carer with you at home during this time is often recommended.

5. What to expect: step by step

Step What happens
1. Pre-medication Steroids, paracetamol and antihistamine before early doses
2. Step-up doses Small doses over the first 1-2 weeks
3. Monitoring Temperature, blood pressure and alertness checked closely
4. Full dose Usually weekly at first, then every 2-4 weeks for some drugs
5. Regular reviews Blood tests and checks for infections
6. Response assessment Scans or bone marrow tests

Blinatumomab’s continuous drip

Blinatumomab is given continuously for 4 weeks through a small portable pump connected to a central line. You carry the pump in a bag and visit the clinic regularly to change the bag. After 4 weeks there is usually a 2-week break before the next cycle.

6. Side effects and risks

Cytokine release syndrome (CRS)

CRS happens when activated T cells release large amounts of chemical messengers called cytokines. It usually causes fever, chills, low blood pressure or low oxygen levels, typically within a day or two of the early doses. Most cases are mild. It is treated with fluids, paracetamol and, if needed, a medicine called tocilizumab or steroids.

Some people develop ICANS (immune effector cell-associated neurotoxicity syndrome). Symptoms include confusion, difficulty finding words, shakiness or drowsiness. Rarely, seizures occur. Driving and operating machinery are usually not allowed for a time after early doses.

Tips for carers

Carers often notice nerve-related side effects before the patient does. Simple checks, such as asking the person to write a short sentence or name everyday objects, can reveal early confusion. If handwriting changes, speech becomes muddled or the person is unusually sleepy, contact the treatment team straight away, using the emergency number you were given.

Other side effects

Side effect Notes
Infections Common and sometimes serious, especially in myeloma
Low blood counts Neutrophils, platelets and red cells
Low antibody levels Some people need antibody replacement infusions
Taste changes, skin and nail changes Particularly with talquetamab
Tiredness Common
Injection-site reactions With injections under the skin

How common are these effects?

In a study of teclistamab in myeloma, CRS occurred in about 72% of people, but almost all cases were mild. Infections occurred in about three-quarters of people (Moreau et al., 2022). In a study of glofitamab in lymphoma, CRS occurred in 63%, with severe CRS in 4% (Dickinson et al., 2022).

7. Results and outlook

Study Main finding
TOWER trial, relapsed ALL, 405 patients Median survival was 7.7 months with blinatumomab versus 4.0 months with chemotherapy; complete remission rates were 34% versus 16% (Kantarjian et al., 2017)
MajesTEC-1, myeloma, 165 patients 63% responded to teclistamab, with a median duration of response of about 18 months (Moreau et al., 2022)
Glofitamab study, DLBCL, 155 patients 39% had a complete response, including people whose lymphoma had come back after CAR-T (Dickinson et al., 2022)
Mosunetuzumab study, follicular lymphoma, 90 patients 60% had a complete response (Budde et al., 2022)

What the results mean

Bispecific antibodies can produce deep and lasting responses in people whose cancers had stopped responding to standard treatments. For some lymphomas, fixed-length treatment courses mean that people can stop therapy if the cancer responds. They are now being tested earlier in the course of disease and in combination with other treatments.

8. Recovery and aftercare

Tip Why
Check your temperature as advised Fever may signal CRS or infection
Carry your alert card Tells other doctors about your treatment
Keep someone nearby in the early weeks Helps spot confusion or other changes
Avoid driving as instructed Because of possible nerve-related side effects
Take preventive medicines Antiviral or antibiotic tablets if prescribed
Report new symptoms early Infections can become serious quickly

Infection prevention

Because these medicines can reduce antibody levels and white cell counts, infections are a major concern, particularly in myeloma. You may be given antibiotics or antivirals to prevent infection, antibody replacement infusions, and advice on vaccinations. Wash hands often and avoid close contact with people who are unwell.

If the treatment stops working

Cancers sometimes stop responding to a bispecific antibody. This can happen because the cancer cells lose the target protein, or because the T cells become exhausted after long periods of stimulation. In this case, your team may suggest a bispecific with a different target, CAR-T cell therapy, other drug combinations or a clinical trial.

Living with ongoing treatment

For drugs given until the cancer grows, treatment becomes part of daily life, with regular clinic visits. Many people continue with work, travel and hobbies between appointments, adapting as needed.

9. Alternatives

Alternative When it is considered
CAR-T cell therapy Another T-cell therapy; personalised but requires manufacturing time
R-CHOP chemotherapy Standard first treatment for diffuse large B-cell lymphoma
Allogeneic stem cell transplant Often after blinatumomab gets ALL into remission
Autologous stem cell transplant Myeloma and some lymphomas
Antibody-drug conjugates Other antibody-based treatments for lymphoma and myeloma
Clinical trials Combinations and newer bispecific antibodies

10. Frequently asked questions

Question Answer
How is this different from CAR-T? CAR-T uses your own modified T cells; bispecifics are ready-made medicines
Will I need to stay in hospital? Often for the first doses, depending on the drug and centre
Can I drive? Not for a period after the first doses; ask your team
Will I lose my hair? Hair loss is not typical
How long will I have treatment? Some drugs are given for a set period; others continue until the cancer grows
What if the cancer loses the target? Sometimes cancer cells stop showing the target protein, and a different treatment is needed
Can I travel during treatment? Usually not in the first weeks; discuss later trips with your team
Do I need a central line? Only for some drugs, such as blinatumomab
Are bispecifics chemotherapy? No, they are immunotherapy
Can I have vaccines? Inactivated vaccines are often advised; live vaccines are avoided

11. Questions to ask your care team

  • Which bispecific antibody do you recommend, and why?
  • Will I need to stay in hospital for the first doses?
  • What signs of CRS or ICANS should my family look out for?
  • How will you prevent infections?
  • How long will treatment last?
  • What are the alternatives, such as CAR-T or a clinical trial?

Resources

  1. Budde, L.E. et al. (2022) ‘Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study’, The Lancet Oncology, 23(8), pp. 1055-1065.
  2. Dickinson, M.J. et al. (2022) ‘Glofitamab for relapsed or refractory diffuse large B-cell lymphoma’, New England Journal of Medicine, 387(24), pp. 2220-2231.
  3. Kantarjian, H. et al. (2017) ‘Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia’, New England Journal of Medicine, 376(9), pp. 836-847.
  4. Moreau, P. et al. (2022) ‘Teclistamab in relapsed or refractory multiple myeloma’, New England Journal of Medicine, 387(6), pp. 495-505.
  5. National Cancer Institute (2026) Blinatumomab. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/blinatumomab (Accessed: October 2026).
  6. National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.